It’s In the News.. a roundup of the top diabetes stories and headlines of the past seven days. This week: the first AID system to use Libre 3 is released, we learn more about Teplizumab, now brand name Tzield, to prevent T1D and how much it may cost. Couple of new research projects about what triggers type 1, a personal story about retinopathy and a player with T1D takes the stage at the World Cup.
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners – they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
And by my new book “Still The World’s Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon in paperback and for kindle.
The first automated insulin delivery system using the FreeStyle Libre 3 is now authorized in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab
Ypsomed already launched mylife Loop in partnership with CamDiab in early summer 2022 in several countries. That was with the Dexcom G6. The company now says By enabling the FreeStyle Libre 3 sensor to work with mylife Loop, people with diabetes now have the option of choosing between two sensors, the Dexcom G6 and the FreeStyle Libre 3, and of customising their loop.
with other European countries to follow in 2023. The mylife Loop offering is currently available for Android, iOS will follow in the second half of 2023.
I spoke with Ypsomed last year, they are partnering with Lilly and plan to bring their pump the US. Right now oly the Dexcom G6 is approved for AID use, so we’ll see if we get the same kind of flexibility.
Really interesting but very early work on protein known as Befa. It’s produced by gut bacteria and triggers the division of cells that make insulin. Reserachers at Univesrty of Utah are working on understanding more about how Befa works.. hoping it could help them figure out a way to stimulate beta cell prdocution. The researchers’ findings were recently published in the journal Cell Metabolism. The finding suggests that bacterial warfare in the gut can have collateral beneficial effects on the body, boosting the population of cells that can make insulin throughout the lifespan. In the future, Guillemin’s team imagines possible therapeutic applications for the finding. For example, proactively fortifying the microbiomes of high-risk infants with BefA-producing bacteria could prevent them from later developing type 1 diabetes.
A new serological test may be pivotal in the search for viral triggers of diseases like diabetes and celiac disease. PepSeq is a technology that allows scientists to test antibody binding against hundreds of thousands of protein targets at one time, instead of testing one at a time. This protocol is laid out in detail in an article published earlier in November in Nature Protocols.
It’s said to be an important step forward as concerns about bioterrorism, zoonotic diseases and the next pandemic are never far away. Understanding these pathogens will help scientists develop vaccines and track their movement and evolution.
“This can help us to better understand the epidemiology of infectious diseases, and it is also empowering us in our search for potential viral triggers for non-infectious diseases like diabetes and celiac disease,” Ladner said.
The recent approval of teplizumab – brand name is now Tzield, for the delay of type 1 diabetes by the US Food and Drug Administration is expected to advance efforts to increase screening to cost-effectively identify those at risk for the condition who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved November 17. In a clinical trial, teplizumab delayed the onset of clinical (stage 3) type 1 diabetes by approximately 2 years, and longer in some cases.. more than 4 years.
It is administered by intravenous infusion once daily for 14 consecutive days and is expected to cost in the region of $200,000 for the course of treatment.
During an investor call on November 18, Provention Bio chief commercial officer Jason Hoitt said that among the company’s “strategic initiatives” were “advancing awareness and screening for autoantibodies in at-risk individuals, and ultimately, routine screening during pediatric well visits for the general population,” as well as “[healthcare provider] belief in teplizumab and desire to prescribe it for their patients.”
Without broad population-based screening, first-degree relatives of people with type 1 diabetes are likely to be the first to be screened and those with stage 2 identified for receipt of teplizumab. Today, that population is estimated at about 30,000 in the United States, Hoitt said, adding, “with this approval we hope that more stage 2 patients can be readily identified so the course of the disease can be changed.”
A new way to test for pancreatic cancer is being considered a breakthrough. Pancreatic cancer is commonly considered the deadliest of all cancers in part because with few symptoms and invasive testing, it’s so difficult to detect. Bluestar Genomics, which has developed a new non-invasive “liquid biopsy” test that uses a blood test.
Pancreatic cancer is eight times as common in patients over the age of 50 with a recent diagnosis of type 2 diabetes. Sometimes, new cases of type 2 diabetes may actually be a consequence of early, undetected pancreatic cancer. Bluestar has breakthrough designation from the FDA. It’s too soon for doctors to recommend this for everyone with type 2 but those recently diagnosed should ask their doctors.
Not really news but a lot of social media chatter about a lame diabetes joke this time during Wednesday, the reboot of the Adams Family. Hearing great things about the show but not the diabetes joke. Good time to mention Diatribes d-stigamtize campaign . I’ll link up the website, it’s an effort to collect stories and to come up with action to fight diabetes stigma.
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
Big shout out to friend of the show – and friend of mine – Mike Hoskins. Mike wrote for diabetesmine for many years and still works at the parent company, Healthline. He recently shared a lot of information and feeling about his diabetic retinopathy diagnosis. He goes into detail of what the treatment has been lie, saying that others sharing that with him has helped make it all a bit easier. Its’a wonderful article and I’ll link it up in the show notes.
Many of you have probably been following Jodan Morris for many years, but just in case.. the 28-year old professional soccer player was diagnosed at age 9. He’s now part of the U.S. Men’s National Team that beat Iran this week and moves ahead to the World Cup knock out rounds this weekend. He plays out of Seattle and has started a foundation, Jordan Morris Foundation, to support kids living with Type 1 Diabetes.
On the podcast next week.. One Drop is making a CGM? We’ll talk to CEO Jeff Dachis about that. Last week’s show was with therapist JoAnne Robb.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.